- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Momenta Pharmaceuticals Inc
Add to PortfolioMNTA:US
13.9700 USD 0.1900 1.38%As of 20:10:00 ET on 05/29/2012.
Snapshot for Momenta Pharmaceuticals Inc (MNTA)
| Open: | 13.9300 | Day's Range: | 13.7100 - 14.1900 | Volume: | 228,207 | Bid: | 13.9600 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 13.7800 | 52wk Range: | 10.1500 - 21.0000 | 1-Yr Rtn: | -29.69% | Ask: | 13.9700 |
Key Statistics for MNTA
| Current P/E Ratio (ttm) | 6.0216 |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | 2.3200 |
| Est. EPS (USD) (12/2012) | -0.8050 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 719.73 |
| Shares Outstanding (M) | 51.52 |
| Enterprise Value (M USD) (ttm) | 337.47 |
| Enterprise Value/EBITDA (ttm) | 2.74 |
| Price/Book (mrq) | 1.7888 |
| Price/Sale (ttm) | 3.0451 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 08/03/2012 |
More MNTA Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for MNTA
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for MNTA
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company specializes in sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. Momenta also develops technology-enabled generic products.
| Craig A WheelerPresident/CEO | Richard P Shea "Rick"Senior VP/CFO |
| Bruce A LeicherSenior VP/Secy/General Cnsl | James M RoachSenior VP:Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page